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Molecular basis of hereditary Clq deficiency associated with SLE and
IgA nephropathy in a Turkish family. Two siblings (case 1 and case 2) with
homozygous Clq deficiency are described. Both presented with a photo-
sensitive rash, and during follow-up case one developed SLE with
nephrotic range proteinuria. Case 2 had microscopic hematuria with a past
history of macroscopic hematuria. Renal biopsies revealed mesangiopro-
liferative glomerulonephritis in case 1 and IgA nephropathy in case 2, a
new finding in association with Clq deficiency. Since the classical pathway
of complement plays a role in the development of antibody responses, the
family was also evaluated for the immune response to hepatitis B vaccine.
Antibody response to hepatitis B vaccine was normal in both affected
members and the rest of the family. The A-, B- and C- chain genes of Clq
were amplified by PCR and directly sequenced. A homozygous C to T
point mutation was identified in genomic DNA isolated from the patients
at codon 186 in the A chain that resulted in a premature stop codon. This
mutation was present in both parents and both unaffected sibs in the
heterozygous state. This mutation was identical to that previously de-
scribed in a Slovakian family with Clq deficiency. Because of this finding,
a series of 92 genomic DNA samples was screened from ethnically distinct
patient groups with SLE to test the hypothesis that this mutation of Clq
may be a widespread disease susceptibility gene. No further examples of
this mutation were found.
Hereditary homozygous Clq deficiency is a rare disease that
was first described in a ten-year-old Turkish boy by Berkel and
colleagues in 1977 [1]. Since then 32 cases of Clq deficiency
associated with recurrent skin lesions, chronic infections, systemic
lupus erythematosus (SLE) or SLE-like diseases, and mesangial
proliferative glomerulonephritis have been reported [reviewed in
2—4].
Clq is composed of 18 polypeptide chains of three different
chain types: A, B and C. The A- B- and C-chain genes are
tandemly arranged 5' to 3' in the order of A, C, B at chromosome
lp34.l to lp36.3 [5—7]. The molecular basis of Clq deficiency has
been described in six cases [4, 8—10]. All the mutations have been
point changes. In three cases there were premature stop codons
[4, 8, 9], in one case a single base deletion [4], and in two cases a
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glycine to arginine amino acid substitution at codon 6 of the
C-chain, causing expression of a dysfunctional protein [4, 10].
Complement plays a role in the generation of antibody re-
sponses and immunological memory [11, 12]. There is evidence
from studies in mice depleted of complement using cobra venom
factor [13] and in C4, C2 and C3 deficient guinea pigs [12] that C3
activation via the classical pathway is an important step in
generating a normal humoral immune response, particularly to
low doses of T cell-dependent antigens. Early components of the
classical pathway of complement play a role in the processing and
removal of immune complexes from the circulation and tissues. In
humans with homozygous deficiency of one of the early compo-
nents of classical complement pathway, the excess formation and
defective clearance of immune complexes may predispose to the
development of glomerulonephritis and autoimmune disease in-
cluding especially SLE [14, 15]. IgA nephropathy has been
described in patients and families with partial deficiency of
regulatory factors properdin (P) or H and in a patient with
homozygous deficiency of C3 [16—18].
In this report we describe a Turkish family in which two siblings
had homozygous Clq deficiency associated with SLE and IgA
nephropathy. We examined the response of the patients and other
family members to immunization with hepatitis B vaccine. We
identified the molecular defect causing the Clq deficiency in this
family and screened 92 genomic DNA samples from patients with
SLE for this particular mutation, using the polymerase chain
reaction (PCR) and restriction enzyme digestion.
Methods
Complement assays
CH5O and AP5O. Classical pathway hemolytic complement
activity was measured by plate assay, using antibody-sensitized
sheep erythrocytes as previously described [19]. The alternative
pathway hemolytic complement activity was measured by plate
assay, using guinea pig erythrocytes in Mg-EGTA buffer as
previously described [19].
Clq. Plasma samples were initially screened by double immu-
nodiffusion assay using sheep polyclonal anti-Clq (The Binding
Site, Birmingham, UK). Antigenic Clq levels were measured by
ELISA as previously described [20].
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Table 1. Oligonucleotides used during the study
Oligonucleotide Chain
Annealing
temperature_(°C) Oligonucleotide sequence—5' to 3'
Oligo position
codon number
CIQA15' A 55 CCGTGTCTCCACAGAGGCATC -29 to -22
C1QA23' A 55 GCATGGAAGCCAGAGAGGTG +240 to +233
C1QAREV' A 60 ATCGTCTCCTCCTCAAGGG +153 to +159
K3 B 55 A'VFGTCTTCTAGACAGGAGGCGTCT -38 to —31
K4 B 55 TGGATGTGAATTCGCCCACAGGTCA +235 to +227
C1QC15' C 58 CCTCCCAGTTCCTI7CTCCGG -21 to -27
C1QC23' C 58 GTGGGTCTCGAGCGCATCTG +227 to +221
JOK-1 A 55 GGTACGGTTCTTCCTGGTI7G +123 to +115
JOK-2 A 55 CTGAAGCACCATGCCCCCTG +186 to +180
JOK-3 B 55 ATGITGGTGATCACGTGGTC + 122 to + 116
JOK-4 B 55 GTCACAGAAGGTGACCACC +172 to +166
JOK-5 C 62 GGGTGCAGGGGGCTGGTGG + 106 to + 100
JOK-6 C 62 GATTGGTVITGGACGTGTGG + 172 to + 166
Other component assays. Cir, Cis, C4, C2, and C3 levels were
measured by single radial immunodiffusion or rocket immuno-
electrophoresis in 1.2% CFD/agarose, using specific polyclonal
antisera (The Binding Site).
Anti-C]q antibodies. Antibodies to Cilq were measured by a
modification of the method described by Seigert and colleagues
[201 as previously described [3].
DNA samples from patients with C]q deficiency and SLE
Samples of genomic DNA were prepared [21] from peripheral
blood from family members: the two patients, both parents and
two unaffected siblings. In order to screen for the mutation
detected in the family, genomic DNA samples were used from 85
Caucasoid and 7 Afro-Caribbean patients fulfilling the 1982 ARA
classification criteria for SLE.
PCR oligonucleotides
Primers K3 and K4 were gift from Professor K.B.M. Reid, and
other primers were synthesized by the Human Molecular Genetics
Group (Cambridge, UK; Table 1).
Amplification of A-B and C-chain genes of Clq by PCR and
sequence analysis
We amplified the complete A-, B- and C-chain genes of Clq
from genomic DNA samples by polymerase chain reaction (PCR).
We used primers C1QA15' and C1QA23' to amplify the A-chain,
K3 and K4 to amplify the B-chain and C1QC15' and C1QC23' to
amplify the C-chain (Table 1). PCR reactions (100 tl final
volume) were performed with ix Taq Extender Buffer (Strat-
agene, La Jolla, CA, USA), 2 m'vi MgCl2, dATP, dCTP, dGTP and
dTTP each at 100 /.LM, 150 ng of forward and reverse primers, 200
ng genomic DNA, 10 units Taq DNA polymerase (Gibco BRL,
Paisley, UK) and 10 units of Taq Extender PCR additive (Strat-
agene). Reaction conditions included initial denaturation at 95°C
for three minutes followed by 30 amplification cycles of 94°C for
45 seconds, annealing temperature for 45 seconds and 72°C for
two minutes 30 seconds, with a final cycle at 72°C for 10 minutes.
The PCR products were quantified on a 0.8% agarose gel in
IxTBE (90 mt Tris-HC1, 90 m boric acid, 2.5 mvt Na2EDTA, pH
8.3). PCR products were purified using the Wizard DNA
Clean-Up System (Promega, Madison, WI, USA). The purified
products were used as template DNA for sequence analysis using
the fmol DNA sequencing system according to manufacturer's
instructions (Promega).
Restriction enzyme analysis of exon 2 of A-chain
We amplified a 260 bp fragment from exon 2 of the A-chain
from genomic DNA samples of all six family members and a panel
of 102 SLE patients by PCR (using the primers C1QA-REV' and
CIQA23'; Table 1). PCR reactions (20 jsl final volume) were
performed with 20 mtt Tris-HCI (pH 8.4), 50 ifiM KCI, 1.5 mM
MgC12, 100 M of each dNTP, 150 ng of each primer, SOng genomic
DNA and 1 unit of Taq DNA polymerase (Gibco BRL). The
reaction conditions were 30 amplification cycles of 94 for 30
seconds, 58 for one minute and 72 for 45 seconds. The PCR
products were digested at 37 for two hours in a 20 tl volume
containing lxReact 6 buffer (Gibco BRL), 5 tl of PCR product,
and 10 units PvuII (New England Biolabs, Beverly, MA, USA).
The fragments were separated on a 3% metaphor agarose gel
(Flowgen, Sittingbourne, Kent, UK) in lx TBE buffer by electro-
phoresis at 50 V for one hour. The mutation observed in this
family causes the loss of a PvuII site such that the PCR product
remains at 260 bp. Normal samples are digested, producing 160 bp
and 100 bp fragments.
Case reports
Case 1. A girl aged 3.5 years presented with a two year history
of photosensitive skin and scalp eruptions, associated with fatigue
and arthralgia. Except for an older sister (Case 2) who had similar
skin lesions, the rest of the family members were healthy. The
parents were not consanguineously related.
Physical examination revealed erythematous desquamative and
hyperkeratotic skin and scalp lesions. There were monilial and
aphthous lesions of her mouth and palate, and finger and toenail
deformity secondary to moniliasis. The rest of the physical
examination was normal. Urinalysis was normal.
Blood tests showed hemoglobin 9 g!dl with an MCV of 71.7 fi
(normal 80 to 100 fi) and serum ferritin level of 84.8 nglml
(normal > 100 ng/ml). Immunoglobulins, direct Coombs' test,
anti-nuclear antibodies (ANA), anti-dsDNA, and anti-cardiolipin
antibodies measured by ELISA and ANA were normal or nega-
tive.
Complement assays showed absent CH5O and no Clq was
detectable by single radial immunodiffusion (Table 2). Following
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Table 2. Complement levels in the family
Normal
Complement protein range Case 1 Case 2 Father Mother Sibling Sibling
CH5O (%NHS)
AP5O (%NHS)
50—125
60—103
0
82
0
85
102 133 88 93
Clq (ELISA) mg/mi 47—211 0 0 79 105 96 53
Cir (rocket i.e.p.) %NHS 74—113 104 104 76 96 92 136
Cis (rocket i.e.p.) %NHS 54—116 102 109 89 89 96 89
C2 (rocket i.e.p.) %NHS 64—108 65 58 — — — —
C3 (Mancini) g/iiter 0.60—1.35 1.48 1.09 1.58 0.88 1.05 1.33
C4 (Mancini) gIlder 0.16—0.38 0.62 0.40 0.25 0.27 0.21 0.31
Anti-Clq autoantibodies (ELISA)AELJXZ <63 21 31 47 39 34 26
a Detection limit of assay was 1 nglml
Not measured
C Arbitrary ELISA units
mixing her serum with a known Clq deficient serum (from
another patient) the CH5O remained at 0%. However, mixing her
serum with 10% of a known C2 deficient serum, or normal serum
(NHS) restored the CH5O to the normal range. These functional
measurements correlated with the antigenic absence of Clq.
Assay results of other complement proteins in the patient and her
relatives are presented in Table 2.
Her rash persisted and at the age of 5.5 she developed
peripheral edema, +4 proteinuria on stick testing and reduced
serum albumin concentration of 25 g/liter during a febrile episode
associated with a culture-negative bronchopneumonia. Her ANA
and anti-dsDNA levels had risen to 335 arbitrary ELISA units
(AEU) (N < 250 AEU) and 750 AEU (normal < 100 AEU),
respectively. Her ANA (1101, 452, 362, and 335 AEU) and
anti-dsDNA levels (385, 342, 126, and 100 AEU) remained high
on four subsequent occasions during a four month period. She was
treated with fresh frozen plasma, IVIG, and antibiotics; however,
proteinuria and hypoalbuminemia persisted and a renal biopsy
was performed.
The renal biopsy showed the typical picture of mesangioprolif-
erative glomerulonephritis with slight mesangial enlargement and
minimal mesangial hypercellularity. By electron microscopy a few
osmiophilic deposits were found along the mesangial basement
membrane and in subepithelial position (Fig. 1). Immunohistol-
ogy could not be performed since only glutaraldehyde-fixed
material was available for investigation.
A course of prednisolone 2 mg/kg was given for four months
and she responded well with resolution of proteinuria, a rise in her
serum albumin level and decrease in her anti-dsDNA level to
normal (5 AEU). Prednisolone was gradually reduced to 10 mg on
alternate days. At the age of 7 autoimmune serological analysis
was repeated at Hammersmith Hospital. ANA and anti-dsDNA
were negative. Anti-Ro antibodies were detected by counterim-
munoelectrophoresis; rheumatoid factor assayed by latex aggluti-
nation was positive at a titer of 1:80, and IgG anticardiolipin
antibodies (ACA), measured by ELISA, were strongly positive
(IgG ACA = 68.7 AEU, normal <9.0 AEU); 1gM ACA were
negative.
Case 2. The sister of case 1 presented at the age of 15 with
photosensitive rash. She had a past history of two isolated
episodes of macroscopic hematuria at age 8 that lasted for two
weeks and resolved spontaneously.
Physical examination revealed erythematous desquamative skin
lesions on her face and hands. The rest of the physical examina-
tion was normal. Urinalysis was normal.
Full blood count, serum urea, creatinine, total protein, albumin,
sedimentation rate, CRP, immunoglobulins, ANA, anti-dsDNA,
anti-cardiolipin antibodies were all within normal limits. When
she was aged 17 an autoimmune serological analysis was repeated
at Hammersmith Hospital. ANA, anti-dsDNA, anti-ENA and
rheumatoid factor were all negative. IgG anticardiolipin antibod-
ies were weakly positive (lgG ACA = 18.8 AEU, normal < 9.0
AEU); 1gM ACA were negative. Complement findings were
identical to those of her sister (Table 2).
During follow-up to the age of 17 she did not have any
recurrence of macroscopic hematuria, however, on five occasions
microscopic hematuria was detected and a renal biopsy was
performed. Light microscopy showed similar findings to those
seen in case 1 (Fig. 2A). Immunohistology showed mesangial
deposits of IgA (Fig. 2B), 1gM, C3 and C5b-9. By electron
microscopy only very small osmiophilic deposits along the mesan-
gial basement membrane were found (Fig. 3). The final diagnosis
was of IgA nephropathy in a case of mesangioproliferative
glomerulonephritis by light microscopy.
Results
Results of sequence analysis of A-B-C chain genes
The complete DNA sequence of A-, B- and C-chain genes of
Clq, including the splice donor and splice acceptor sites was
determined in genomic DNA derived from Case 1. A homozygous
C to T transition at codon 186 in the A chain was identified. The
same mutation was present in homozygous form in the other
patient (case 2) and both of the parents and the two unaffected
sibling were found to be heterozygous for this mutation by
sequence analysis. Figure 4 shows the mutation in homozygous
form in one of the affected siblings and in a heterozygous form in
the mother in comparison with the sequence from a normal
individual. This mutation causes a change from CAG to TAG at
codon 186 that results in a premature stop codon, and also causes
a loss of a recognition site for the restriction enzyme PvulI. No
other coding abnormalities were found in any remaining Clq
A-gene or the B- or C-chain genes.
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Fig. 1. A and B. Peripheral glomentlar loop with
adjacent mesangium. There are numerous
osmiophilic deposits on the outside of the
basement membrane which are partly
surrounded by newly formed basement
material.
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Fig. 3. Peripheral glomerular loop with adjacent mesangium. Note the
band-like osmiophilic deposits along the mesangial basement membrane.
No peripheral deposits were found.
Fig. 2. A. Mesangioproliferative glomerulonephritis. There is mesangial
enlargement with mesangial hypercellularity. B. Extensive IgA deposits in
the mesangium. The deposits for 1gM, C3 and C5b-9 showed a similar
pattern of distribution. Immunochemistiy was performed on paraffin-
embedded tissue according to standard methods after pronase pre-treatment.
Results of restriction enzyme digestion analysis of the A chain
PCR product
Digestion with PvuII of the PCR product from exon 2 of A
chain confirmed that both patients are homozygous for the
mutation. The 260 bp PCR products were resistant to digestion
with PvuH, consistant with the loss of the PvuII site, due to the C
to T transition at codon 186 (Fig. 5). Both parents and both
unaffected sibs were confirmed as heterozygous for this mutation
as there were three bands observed of 260 bp, 160 bp and 100 bp.
This corresponds to the presence of one wild type and one mutant
allele (Fig. 5).
This mutation is the same as that previously reported in a
Slovakian patient with Clq deficiency [9, 22]. The finding of the
same mutation responsible for cases of homozygous Clq defi-
ciency in geographically-disperse patients suggests that the muta-
tion might be of some antiquity. This prompted us to ask whether
the same mutation might be found in other patients with SLE and
conceivably could cause increased disease susceptibility when
expressed in heterozygous form. We screened genomic DNA
samples from 92 patients with SLE by PvuII digestion of the
A-chain exon 2 PCR. The samples from the homozygous patient
and heterozygous parents were used as positive controls. All of
the 92 samples produced the 100 and 60 bp products, which
indicates the presence of the recognition site for PvuII. It is
therefore unlikely that the mutation identified in this family is a
significant disease susceptibility gene in the population of lupus
patients as a whole.
Immunization of the patients with hepatitis B vaccine
The two patients with Clq deficiency were vaccinated against
hepatitis B with recombinant hepatitis B vaccine (Gen Hevac B,
Pasteur Merieux, France). Both had no specific anti-HBS anti-
body before vaccination, and both had a normal lgG antibody
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Fig. 4. DNA sequence of a normal individual, mother of case 1, and case I using sequencing oligonucleotide CJQA23'. The PCR product of the complete
A-chain gene was used as template DNA. The gel was electrophoresed for 2.5 hours at 1.1 kV. The autoradiogram was exposed for 24 hours. Case 1
shows a C to T nucleotide change marked by an asterisk, resulting in a premature stop codon, TAG. The mother is a CIT heterozygote at this position.
Fig. 5. Digestion of PCR product from exon 2 of the A-chain with restriction enzyme PvuII. The family tree is shown at the top, with the affected status
displayed. The PCR fragments were separated on a 3% Metaphor agarose gel in I >< TBE, electrophoresed at 40 V for 90 minutes and stained with
ethidium bromide. DNA size standards are 250 ng PhiX 174 DNA digested with HaeIII. The lanes contain digested PCR product from a normal
individual, father, case 2, two unaffected siblings, case 1, mother and a negative control for the PCR reaction. The uncut product is 260 bp and the two
fragments produced by digestion are 160 and 100 bp. The parents and unaffected sibs are confirmed as heterozygotes for the loss of the PvuII site and
the two patients are homozygous for the loss of the PvuII site.
response with levels of 128300 and 131690 lU/liter (normal >
1250 lU/liter) four weeks after the last of the three injections.
Discussion
There are three points for discussion in relation to this new
family with homozygous Clq deficiency: (i) the finding of a
mutation identical to that previously reported in a Slovakian
family; (ii) the presence of IgA nephropathy in case 2; and (iii) the
normal response to hepatitis B vaccination.
Clq deficiency presents in two different forms, absent Cl q
protein or presence of a dysfunctional molecule. The molecular
basis of both forms of deficiency has been characterized in six
cases [4, 8—10]. The first molecular lesion, reported by McAdam,
Goundis and Reid [8], was a homozygous G to A mutation at
residue 150 in the B-chain resulting in a premature stop codon.
The second report was of a point mutation at codon G1n186
(CAG to TAG) in the globular region of the A chain, which also
caused a premature stop codon [9, 22]. The other four mutations
were found in C chain. One patient had a homozygous deletion of
a C nucleotide at position 43 of the C chain, resulting in a frame
shift with premature stop codon in frame at position 108 [4], the
other had a homozygous C to T mutation at position 41 of the
C-chain resulting in a premature stop codon [41 Two further cases
presented with dysfunctional Clq deficiency from two racially
distinct groups but showed the same homozygous point mutation
(G to A) at position 6 of the C chain [4, 10]. Thus mutations have
been found in all three chains of Clq and all were either single
base pair deletions or single base pair mutations. No example has
been identified of dominant Clq deficiency caused by expression
of a poisonous polypeptide chain, as has been described for
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another member of the collectin family of molecules, the mannose
binding protein [23].
The patients presented here have the same mutation to that
previously reported in a Slovakian family [9, 22]. The molecular
basis of Clq deficiency has now been determined in patients from
seven families. It is remarkable that among this small number of
families two mutations have each been found in two families. The
two families sharing each mutation were widely separated, in one
case geographically (Central Turkey and Slovakia), and in the
other geographically and ethnically (Punjabi from India and
Sudeten-German). There are two explanations for these findings:
(i) that the mutations are ancient and therefore widely distrib-
uted; or (ii) that the same mutations have arisen spontaneously on
two occasions. We performed a limited test of the first hypothesis
by screening a population of predominantly Western European
Caucasoid patients with SLE to see if further examples of either
of these mutations could be identified, and to test the hypothesis
that heterozygous deficiency of Clq might increase disease sus-
ceptibility to the development of SLE. We did not find further
examples of either mutation [4, and the present report]. We are
currently collecting samples from other Turkish patients with SLE
to see how widespread the mutation is in the local population. In
this context it is interesting to note that the parents of the two
patients described in this report were not known to be consan-
guineously related, and that other Turkish patients with the Clq
deficiency have been described [1, reviewed in 3].
There have been a number of reports of associations of
complement deficiency with the development of IgA nephropathy.
A 23-year-old Japanese male with a homozygous C3 deficiency
presented with a three year history of proteinuria and microhe-
maturia, and a renal biopsy showing marked deposition of IgA in
glomerular mesangium [18]. IgA nephropathy has also been
described in patients with less well characterized, familial abnor-
malities in expression of complement Factor H and properdin [16,
17]. Three patients have been described with hereditary angio-
edema from a single family who all developed IgA nephropathy
[241. Hereditary angioedema is associated with severe and persis-
tent hypocomplementemia of C4 and C2 secondary to the failure
of regulation of activated Cis in the presence of heterozygous Cl
inhibitor deficiency. Hereditary angioedema is also associated
with the development of SLE [25]. The etiology of IgA nephrop-
athy is unknown, however, these rare associations of IgA nephrop-
athy with hereditary and acquired complement deficiencies im-
plies that a normally functioning complement system may provide
some protection against the development of this disease.
There is a substantial body of evidence that complement plays
an important role in the antibody response [reviewed in 11, 12,
26—28]. In animal models it was found that there was a defect in
antibody responses that was a function of the immunizing dose of
antigen. By using high doses of bacteriophage 1X174 as an
immunogen, the titers of the primary and secondary antibody
responses in complement-deficient guinea pigs approached nor-
mal, but the normal switch from 1gM to IgG did not occur as part
of the secondary response and the IgG anti-X174 antibody
response was markedly impaired [27, 281.
Experimental studies of immunization of complement deficient
patients are few and far between. The South African patient with
C3 deficiency studied by Alper and colleagues [29] showed a
normal anamnestic response to diphtheria toxoid and a normal
primary antibody response to the polyribose phosphate antigen of
H. influenzae in terms of quantitative antibody response. Two C3
deficient subjects were immunized with 1X174 and these patients
demonstrated normal titers of antibody following both primary
and secondary immunizations, but a failure to switch the antibody
response from 1gM to IgG [30]. A further patient with C3
deficiency was given a primary immunization with hemocyanin
and was reported to show a reduced response [31]. This same
subject showed a fourfold increase in titer in response to second-
ary immunization with diphtheria, tetanus, and pertussis vaccine,
which was considered normal [31]. A further patient showed a
normal anamnestic response to typhoid immunization [32].
Our two patients with Clq deficiency were vaccinated against
hepatitis B with recombinant hepatitis B vaccine. Both had no
specific anti-HBS antibody before vaccination, and both had a
normal IgG antibody response four weeks after the last of the
three injections. Thus, in these two Clq deficient patients, the
total lack of classical pathway function did not impair a normal
immune response towards HBSAg vaccine.
This family takes the total number of patients with homozygous
Clq deficiency reported to 34. All but one of the patients had SLE
or an SLE-like illness. Clq deficiency, although very rare, is a
powerful disease susceptibility gene for the development of SLE.
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